Multiplex Assay Kit for Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) Canis familiaris; Canine (Dog) Multiplex ELISA

CCL3; MIP1-A; SCYA3; Chemokine C-C-Motif Ligand 3; Small Inducible Cytokine A3; Homologous To Mouse Mip-1a; Tonsillar Lymphocyte LD78 Alpha Protein

(Note: Up to 8-plex in one testing reaction)

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Multiplex Assay Kit for Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) Results demonstration
  • LMA092Ca.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 80-94 88
EDTA plasma(n=5) 78-98 86
heparin plasma(n=5) 84-95 92
sodium citrate plasma(n=5) 79-97 84

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 88-105% 88-105% 87-101% 90-99%
EDTA plasma(n=5) 78-95% 98-105% 82-92% 83-103%
heparin plasma(n=5) 80-101% 90-97% 82-99% 89-103%
sodium citrate plasma(n=5) 85-101% 97-104% 84-92% 84-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:MIP1a) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

Multiplex Assay Kit for Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay)

Test principle

Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.

Giveaways

Citations

  • Age influence on hypersensitivity pneumonitis induced in mice by exposure to Pantoea agglomeransPubmed: 24044680
  • The Transcriptional Foundations of Sp110-mediated Macrophage (RAW264. 7) Resistance to Mycobacterium tuberculosis H37RaPubmed:26912204
  • CIRCULATING MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (MIP1-Α) AS A POTENTIAL BIOMARKER FOR THE DIAGNOSIS OF PATIENTS WITH …57e97ac908aeb34bc08fd41a.pdf
  • Role of Gut-Derived Endotoxin on Type I Collagen Production in the Rat Pancreas after Chronic Alcohol Exposure pubmed:29121396
  • Changes in the concentrations of inflammatory and oxidative status biomediators (MIP-1 α, PMN elastase, MDA, and IL-12) in depressed patients with and without posttraumatic stress disorder10.1016/j.pharep.2017.08.008
  • Molybdenum disulfide/graphene oxide nanocomposites show favorable lung targeting and enhanced drug loading/tumor-killing efficacy with improved …Articles:am2017225
  • Therapeutic Potential of Pien Tze Huang on Experimental Autoimmune Encephalomyelitis RatPubmed:29682587
  • Cathelicidin LL-37 affects surface and intracellular Toll-like receptor expression in tissue mast cellsPubmed:29670923
  • Changes in the concentrations of inflammatory and oxidative status biomediators (MIP-1 α, PMN elastase, MDA, and IL-12) in depressed patients with and without …Pubmed:29339257
  • CQPC06 Activity Prevents Dextran Sulfate Sodium‐Induced Colitis by Regulating the IL‐8 PathwayDoi: 10.1111/1750-3841.14346
  • The anti-inflammatory and anti-oxidative effects of conbercept in treatment of macular edema secondary to retinal vein occlusionPubmed: 30558792
  • Intravitreal conbercept improves outcome of proliferative diabetic retinopathy through inhibiting inflammation and oxidative stressPubmed: 33227274
  • α-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in micePubmed: 32973325
  • PIGU promotes hepatocellular carcinoma progression through activating NF-κB pathway and increasing immune escapePubmed: 32971102
  • A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapyPubmed: 32332752
  • PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L134325342

Recommend products